Hello Dana, I have missed working with you and happy to see that you are working for Sapience and GBM. My mother passed 25 years ago from GBM at a time when treatments were NOT promising. Thank you to Sapience for fighting GBM!
Combining this agent with sotorasib has demonstrated improvements vs sotorasib monotherapy by yielding deeper tumor regressions and reducing the occurrence of disease relapse based on preclinical proof-of-concept data.
https://lnkd.in/gJYkBpcJ#NSCLC#cancer#oncology
Are you an #oncology researcher looking for a way to develop patient-derived tumoroids for your workflow? As the only tumoroid-specific media on the market, OncoPro puts the OG in oncolOGy. (That took me longer to come up with than I care to admit.)
Click below to learn more!
#thermofisherscientific#badpuns#tumoroid
𝗜𝗡𝟴𝗕𝗶𝗼 𝗗𝗼𝘀𝗲𝘀 𝗙𝗶𝗿𝘀𝘁 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗶𝗻 𝗣𝗵𝗮𝘀𝗲 𝟮 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹 𝗼𝗳 𝗜𝗡𝗕-𝟰𝟬𝟬 𝗶𝗻 𝗡𝗲𝘄𝗹𝘆 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝗲𝗱 𝗚𝗹𝗶𝗼𝗯𝗹𝗮𝘀𝘁𝗼𝗺𝗮
Congrats to the entire team at IN8bio who've just announced that the first patient in their Phase 2 trial for INB-400, an innovative gamma-delta T cell therapy, has been successfully dosed at the Cleveland Clinic in Ohio.
This trial is a major step forward in the fight against glioblastoma multiforme, a highly aggressive brain cancer.
INB-400 combines the power of gamma-delta T cells with standard treatments like temozolomide to offer new hope for GBM patients.
#GammaDeltaTCells#CGT#In8Bio
First-in-human clinical data of our anti-IGSF8 program GV20-0251 was presented at #ESMO2024 today. We are one step closer to bringing a potential therapy for cancer patients. Read more here:
https://lnkd.in/ehA_nhw7#Oncology#ESMO2024#GV20
What an exciting journey for our team to manufacture these novel TIL therapies through the various iterations to reach patients quickly. With the added multi-center study, our teams quickly adapted to integrate cryopreservation into the manufacturing process so patients not just at MD Anderson Cancer Center but other leading cancer centers around the country, have access to this clinical trial.
Congratulations to @obsidian and @rodabe Amaria for this amazing news.
“The distinct manufacturing process of OBX-115 also ensures a desirable TIL phenotype—memory T-cells and CD8+ T cells—that are less exhausted and more robust in their anti-cancer activity. For patients battling metastatic melanoma, OBX-115 could open doors to a treatment that is not only more bearable but also more efficacious. The elimination of IL-2 from the treatment regimen is poised to broaden patient eligibility, inviting those who previously might have had to forego this promising therapy due to the inability to tolerate or access IL-2 including elderly patients.”
https://lnkd.in/g6m57Nch
It is extraordinary what Obsidian Therapeutics has accomplished since our partnership was formed in November 2020: IND clearance of TIL therapy OBX-115, launch of Phase 1 clinical trials with Dr. Rodabe Amaria at MD Anderson Cancer Center, the celebration around $115M of Series B funding, the launch of the multi-center trial, and now…positive Phase I clinical data!
Our partnership with Obsidian demonstrates how collaboration accelerates the entire cell therapy lifecycle, so proof of concept is achieved 3-9 months faster than average. Congratulations to Obsidian on this huge milestone. We are proud to partner with you to develop and manufacture TIL for solid tumors.
We are extra proud of the agility of our teams to help Obsidian bring these therapies into the clinic. We look forward to continuing amazing work with Obsidian in 2024 and beyond.
Jane Koo, PhDIvy LaiChantale BernatchezMarie-Andrée Forget#biotech#celltherapy#endcancerhttps://lnkd.in/gCz6aHQu
Tubulis GmbH doses first patient in phase 1/2a trial investigating #ADC candidate TUB-040 in ovarian cancer and lung adenocarcinoma (NSCLC). TUB-040 is a NaPi2b-targeting Exatecan ADC based on Tubulis’ proprietary linker technology with better biophysical properties that demonstrated effective and durable responses in a range of preclinical models.
ℹ Read more: https://lnkd.in/gEZhZcaM
Business Development Manager at Euromed Pharma
4moWe would love to work with you on your drug sourcing for your upcoming ph2b trials for ST101. Would you be available to chat next week?